Teva Neuroscience, Inc. Release: Post-Hoc Data Analyses Published in Annals of Neurology Found COPAXONE(R) Significantly Delayed Accumulated Disability in Male Patients with Primary Progressive Multiple Sclerosis (PPMS)

KANSAS CITY, Mo.--(BUSINESS WIRE)--Data from the full cohort of the PROMiSE study showed that treatment with COPAXONE® (glatiramer acetate injection) did not reach a significant effect on the primary endpoint of accumulated delay to disability versus placebo in the entire population of patients with primary progressive multiple sclerosis (PPMS) (39.6 percent versus 45.2 percent respectively, p = 0.1753). However, post-hoc analyses demonstrated that COPAXONE® significantly delayed time to progression of accumulated disability in male patients in the study (n=455) who received treatment versus those who received placebo (p = 0.0193). Results of the randomized, double-blind study of over 900 patients were published in a recent issue of Annals of Neurology.

Back to news